Response to the commentary on "Are all measures of liver Kpuu a function of FH, as determined following oral dosing, or have we made a critical error in defining hepatic drug clearance?"
{"title":"Response to the commentary on \"Are all measures of liver Kp<sub>uu</sub> a function of F<sub>H</sub>, as determined following oral dosing, or have we made a critical error in defining hepatic drug clearance?\"","authors":"Leslie Z Benet, Jasleen K Sodhi","doi":"10.1016/j.ejps.2025.107088","DOIUrl":null,"url":null,"abstract":"<p><p>Recently, Sugano commented on our above-titled publication stating that he was a reviewer for the paper. In the Acknowledgements, Sugano indicated that we \"kindly suggested publishing the reviewer report as an article\". What we had actually written was: \"prior to accepting the [unidentified] reviewer's approach, however, we believe he/she would have to publish a paper justifying the methodology and proposing how in vivo clinical data could be analyzed with such methodology\". We further explained the fallacy of the accepted mechanistic models of hepatic elimination in a subsequent manuscript titled \"Pharmacokinetic theory must consider published experimental data\", published online a month after the Sugano commentary became available -not in time for the author to review the full explanation before his commentary was published. Our above-titled publication makes no assumptions or discussions regarding how Kp<sub>uu</sub> should be measured, the major topic of the Sugano paper. Here we detail why the commentary methodology is not relevant to our demonstration that the present mechanistic models of hepatic elimination all lead to the unlikely conclusion that Kp<sub>uu</sub> cannot exceed unity and is related to F<sub>H</sub>. We also detail why the Extended Clearance Model should not be used for in vitro-in vivo extrapolation.</p>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":" ","pages":"107088"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejps.2025.107088","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Recently, Sugano commented on our above-titled publication stating that he was a reviewer for the paper. In the Acknowledgements, Sugano indicated that we "kindly suggested publishing the reviewer report as an article". What we had actually written was: "prior to accepting the [unidentified] reviewer's approach, however, we believe he/she would have to publish a paper justifying the methodology and proposing how in vivo clinical data could be analyzed with such methodology". We further explained the fallacy of the accepted mechanistic models of hepatic elimination in a subsequent manuscript titled "Pharmacokinetic theory must consider published experimental data", published online a month after the Sugano commentary became available -not in time for the author to review the full explanation before his commentary was published. Our above-titled publication makes no assumptions or discussions regarding how Kpuu should be measured, the major topic of the Sugano paper. Here we detail why the commentary methodology is not relevant to our demonstration that the present mechanistic models of hepatic elimination all lead to the unlikely conclusion that Kpuu cannot exceed unity and is related to FH. We also detail why the Extended Clearance Model should not be used for in vitro-in vivo extrapolation.
期刊介绍:
The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development.
More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making.
Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.